Kofi A. P.
- Country
- Hungary
- Department
- Dept of Radiooncology
Research Overview
- Sacituzumab Tirumotecan With or Without Bevacizumab Versus Standard of Care in Patients With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following Platinum-Based Chemotherapy
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
- Efficacy and Safety Evaluation of Luveltamab Tazevibulin Versus Investigator's Choice Chemotherapy in Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing FOLR1
Data & Insights
Has run more than one trial at 144 of 299 partner sites.
Specializations
Thoracic oncology
The investigator is actively involved in clinical research on non-small cell lung cancer and small cell lung cancer, with interest across locally advanced, metastatic, resectable, and treatment-naïve settings. Work in this area also includes biomarker-defined populations and studies centered on PD-L1 expression.
- NSCLC
- SCLC
- PD-L1-positive lung cancer
- Locally advanced and metastatic disease
Therapeutic interests extend to immunotherapy, targeted therapy, and combined treatment approaches in lung cancer management.
Breast and gynecologic oncology
Clinical trial activity includes extensive involvement in advanced breast cancer, early breast cancer, ovarian cancer, endometrial cancer, and related gastroesophageal and gynecologic malignancies. The portfolio reflects interest in hormone receptor-defined disease, HER2-directed treatment, and platinum-sensitive or platinum-resistant settings.
- Advanced breast cancer
- Ovarian cancer
- Endometrial cancer
- HER2-directed and endocrine-based therapy
Research activity also covers maintenance strategies and treatment options for recurrent and metastatic disease.
Hematologic malignancies
The investigator is engaged in studies of lymphoma, leukemia, multiple myeloma, and myelodysplastic syndromes, including both newly diagnosed and relapsed or refractory disease. This area also includes chronic lymphocytic leukemia, mantle cell lymphoma, and follicular lymphoma.
- Diffuse large B-cell lymphoma
- Acute myeloid leukemia
- Multiple myeloma
- Myelofibrosis and myeloproliferative neoplasms
Therapeutic focus includes cellular therapy, antibody-based treatment, and disease control in high-risk hematologic cancers.
Genitourinary and gastrointestinal cancers
Research involvement spans prostate cancer, bladder cancer, urothelial carcinoma, renal cell carcinoma, and gastric cancer. The investigator is also involved in studies of gastroenteropancreatic neuroendocrine tumors and colorectal cancer with molecularly defined features.
- Prostate cancer
- Bladder and urothelial cancer
- Renal cell carcinoma
- Gastrointestinal malignancies
These activities reflect interest in androgen receptor–directed therapy, immune-based treatment, and other precision oncology approaches.
Neurology, immunology, and inflammatory disease
The investigator also participates in clinical research on acute ischemic stroke, multiple sclerosis, myasthenia gravis, immune thrombocytopenia, and inflammatory bowel disease. Additional interest extends to neuropsychiatric and autoimmune conditions, including major depressive disorder, schizophrenia, and chronic inflammatory demyelinating polyneuropathy.
- Stroke prevention and recovery
- Autoimmune neurologic disorders
- Inflammatory bowel disease
- Immune-mediated hematologic disorders
Therapeutic interests include immunomodulation, anti-inflammatory treatment, and interventions for neurologic disability and relapse prevention.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.